News | December 26, 2023
Astellas completes acquisition of Propella Therapeutics
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
Demonstrate significant bleed reduction in hemophilia A and B
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Subscribe To Our Newsletter & Stay Updated
